Lina Salman

Dr. Lina Salman


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
LSLina Salman
Lina Salman
AKAnjali Kulkarni
Anjali Kulkarni
JMJacob D. McGee
Jacob D. McGee
We aimed to evaluate the impact of malnutrition on post-operative mortality and complications in patients undergoing surgery for ovarian cancer (OC). In this retrospective cohort study utilizing the ACS NSQIP database (2013-2022), all individuals with a diagnosis of OC were included. Patients were classified as having “malnutrition” if they met any of the following: (1) pre-operative albumin level <3.5 g/dL; (2) ≥10% weight loss over 6 months + BMI = 18.5–20 kg/m2 in patients <70 years old or BMI = 18.5–22 kg/m2 in patients ≥70 years); and (3) BMI < 18.5. Baseline characteristics, 30-day post-operative mortality and complications were compared between “malnutrition” and “no malnutrition” groups. Of the 20,174 included, 8744 (43.3%) had malnutrition and 11,430 (56.7%) had no malnutrition. The malnutrition group had longer total length of hospital-stay (mean days 4.78 vs. 4.17, p < 0.0001), higher rates of venous thromboembolism, and higher cardiac morbidity compared to “no malnutrition”. On univariate analysis, mortality was higher in the “malnutrition” group (0.8% vs. 0.3%, p < 0.0001). This remained significant after adjusting for potential confounders (aOR 2.92, 95% CI 1.92–4.43, p < 0.0001). In conclusion, in patients undergoing surgery for OC, malnutrition increased the risk of post-operative mortality and complications. Malnutrition assessment should be integrated in pre-operative counseling in patients undergoing surgery for OC.

1 June 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
KMKim Ma
Kim Ma
BTBasile Tessier-Cloutier
Basile Tessier-Cloutier
AAAlon D Altman
Alon D Altman
Mark S. CareyMark S. Carey
Mark S. Carey
JEJosee-Lyne Ethier
Josee-Lyne Ethier
MBMelica N. Brodeur
Melica N. Brodeur
Background: Folate receptor alpha (FRα), commonly expressed in epithelial ovarian cancers, is a clinically actionable biomarker following approval of the antibody–drug conjugate mirvetuximab soravtansine (MIRV). Pivotal trials showed that high FRα expression predicts MIRV benefit, creating the need for standardized testing to ensure timely, equitable access. Methods: To address the need for guidance on FRα testing, the Society of Gynecologic Oncology of Canada convened a multidisciplinary Expert Panel to review the evidence and integrate Canadian clinical, pathology, laboratory, and patient perspectives. Consensus recommendations were developed through structured evidence review, expert discussion, iterative revision, and patient partner input. Results: The panel issued recommendations on the clinical role and timing of FRα testing, tissue requirements, assay selection and validation, interpretation and reporting standards, laboratory quality assurance, reimbursement, and equitable access. It is recommended that FRα testing be available to all patients with epithelial ovarian cancer, with results available no later than platinum-resistant disease, using a validated assay, preferably the Ventana FOLR1 RxDx assay or an appropriately validated laboratory-developed test. Standardized synoptic reporting, participation in external quality assurance programs, and clear patient communication were deemed essential. Conclusions: These recommendations aim to promote integrated, equitable, standardized FRα testing across Canada and support timely identification of patients eligible for FRα-directed therapy, clinical trial enrollment, and future biomarker-driven treatment strategies.